<p><strong>經驗豐富的生命科學領導者推動全球商業戰略，加速早期和晚期生物製劑項目的增長</strong></p>
<p>, /PRNewswire/ -- 藥明康德（Avid Bioservices, Inc.），一家專注於生物製劑合同開發和製造的組織（CDMO），今天宣佈任命 Kerri McCullough Wood 為首席商業官。</p>
<p>繼續閲讀</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null"/></p>
<p>Kerri McCullough Wood，藥明康德首席商業官</p>
<p>McCullough Wood 是一位經驗豐富的生物製藥高管，擁有近三十年的 API、CDMO 和藥品服務經驗。她在加入藥明康德之前，曾擔任 Teva 旗下 TAPI 的首席商業官，負責一個跨越 15 個國家的全球組織，執行商業戰略，加速增長計劃，與全球製藥公司建立強有力的合作關係，並提升整個業務的組織績效。</p>
<p>在她的角色中，McCullough Wood 將領導藥明康德的全球商業組織，包括業務發展、市場營銷和戰略合作伙伴關係。她將專注於加速產品管道的增長，加強客户關係，並進一步將藥明康德的商業戰略與其在早期開發到商業製造的擴展能力對齊。</p>
<p>&#34;Kerri 在公司重要的時刻加入藥明康德，&#34;藥明康德集團總裁兼首席執行官 Kenneth Bilenberg 表示。&#34;我們在早期階段的卓越中心進行了重大投資，並擴大了我們的製造能力，以滿足對美國本土生物製劑開發和製造日益增長的需求。Kerri 帶來了強大的合作、運營卓越和項目執行的成功記錄，這將幫助我們繼續為我們服務的客户和患者提供支持。&#34;</p>
<p>McCullough Wood 的任命正值藥明康德繼續擴大其運營，以支持生物製藥公司在整個開發生命週期中的需求，從早期項目到商業製造。該公司專注於速度、質量和運營可預測性，加上其美國本土的製造能力，使其能夠滿足行業對可靠和響應迅速的 CDMO 合作伙伴日益增長的需求。</p>
<p>&#34;我很高興在藥明康德如此關鍵的增長時刻加入，&#34;McCullough Wood 表示。&#34;公司在質量、靈活性和合作方面建立了良好的聲譽。我期待與團隊合作，擴大我們的商業覆蓋面，加深客户關係，並幫助將更多療法帶給患者。&#34;</p>
<p>在 McCullough Wood 的領導下，藥明康德將繼續推進其使命，設定生物製劑製造的質量和合作標準，使能夠提供改變患者生活的療法。</p>
<p><strong>關於藥明康德</strong></p>
<p>藥明康德是一家全球合同開發和製造組織（CDMO），專注於哺乳動物細胞培養製造。總部位於美國，擁有無可挑剔的 FDA 記錄，藥明康德因其敏捷性、質量和應對複雜全球監管環境的能力而受到全球生物製藥創新者的信任。藥明康德擁有支持新興生物科技和大型跨國製藥公司的經驗，提供從開發到商業供應的端到端解決方案。</p>
<p>藥明康德的數字：</p>
<p>製造超過 600 批次</p>
<p>全球交付超過 275 批次商業產品</p>
<p>7 個以上獲批的商業產品</p>
<p>在主要監管機構進行 10 次成功的預批准/預許可檢查</p>
<p>來源：藥明康德</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTExJk5ld3NJdGVtSWQ9TEE1NjM3MSZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTExMzI3UFJfTkVXU19VU1BSX19fX19MQTU2Mzcx?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTExJk5ld3NJdGVtSWQ9TEE1NjM3MSZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTExMzI3UFJfTkVXU19VU1BSX19fX19MQTU2Mzcx"/></p>

CDMO

<p>Avid Bioservices, Inc. 任命 Kerri McCullough Wood 為首席商務官。她在生物製藥領域擁有近 30 年的經驗，將負責全球商業戰略，專注於業務發展和加強客户關係。她的任命是在 Avid 擴大運營以滿足對生物製劑開發和製造日益增長的需求之際。McCullough Wood 旨在提升 Avid 的商業覆蓋範圍，並支持將療法交付給患者。Avid 是一家值得信賴的合同開發和製造組織（CDMO），以其在生物製藥行業的質量和靈活性而聞名</p>

<p><strong>Experienced life sciences leader to drive global commercial strategy and accelerate growth across early- and late-phase biologics programs</strong></p>
<div class="lb-trans"><p><strong>經驗豐富的生命科學領導者推動全球商業戰略，加速早期和晚期生物製劑項目的增長</strong></p>
</div><p>, /PRNewswire/ -- Avid Bioservices, Inc., a dedicated biologics contract development and manufacturing organization (CDMO), today announced the appointment of Kerri McCullough Wood as Chief Commercial Officer.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- 藥明康德（Avid Bioservices, Inc.），一家專注於生物製劑合同開發和製造的組織（CDMO），今天宣佈任命 Kerri McCullough Wood 為首席商業官。</p>
</div><p>Continue Reading</p>
<div class="lb-trans"><p>繼續閲讀</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null" alt="" original-src="https://www.prnewswire.com/news-releases/null"/></p>
<p>Kerri McCullough Wood, Chief Commercial Officer, Avid Bioservices, Inc.</p>
<div class="lb-trans"><p>Kerri McCullough Wood，藥明康德首席商業官</p>
</div><p>McCullough Wood is a seasoned biopharma executive with nearly three decades of experience across API, CDMO, and drug product services. She joins Avid following her role as Chief Commercial Officer at TAPI, a division of Teva, where she led a global organization spanning 15 countries and was responsible for executing commercial strategy, accelerating growth initiatives, building strong partnerships with global pharmaceutical companies, and enhancing organizational performance across the business.</p>
<div class="lb-trans"><p>McCullough Wood 是一位經驗豐富的生物製藥高管，擁有近三十年的 API、CDMO 和藥品服務經驗。她在加入藥明康德之前，曾擔任 Teva 旗下 TAPI 的首席商業官，負責一個跨越 15 個國家的全球組織，執行商業戰略，加速增長計劃，與全球製藥公司建立強有力的合作關係，並提升整個業務的組織績效。</p>
</div><p>In her role, McCullough Wood will lead Avid's global commercial organization, including business development, marketing, and strategic partnerships. She will focus on accelerating pipeline growth, strengthening client relationships, and further aligning Avid's commercial strategy with its expanding capabilities across early-phase development through commercial manufacturing.</p>
<div class="lb-trans"><p>在她的角色中，McCullough Wood 將領導藥明康德的全球商業組織，包括業務發展、市場營銷和戰略合作伙伴關係。她將專注於加速產品管道的增長，加強客户關係，並進一步將藥明康德的商業戰略與其在早期開發到商業製造的擴展能力對齊。</p>
</div><p>&#34;Kerri joins Avid at an important time for the company,&#34; said Kenneth Bilenberg, Group President and Chief Executive Officer of Avid Bioservices. &#34;We've made significant investments in our early-phase Center of Excellence and expanded our manufacturing capabilities to meet growing demand for U.S.-based biologics development and manufacturing. Kerri brings a strong track record of partnership, operational excellence, and program execution that will help us continue delivering for the clients and patients we serve.&#34;</p>
<div class="lb-trans"><p>&#34;Kerri 在公司重要的時刻加入藥明康德，&#34;藥明康德集團總裁兼首席執行官 Kenneth Bilenberg 表示。&#34;我們在早期階段的卓越中心進行了重大投資，並擴大了我們的製造能力，以滿足對美國本土生物製劑開發和製造日益增長的需求。Kerri 帶來了強大的合作、運營卓越和項目執行的成功記錄，這將幫助我們繼續為我們服務的客户和患者提供支持。&#34;</p>
</div><p>McCullough Wood's appointment comes as Avid continues to scale its operations to support biopharma companies across the full development lifecycle, from early-phase programs through commercial manufacturing. The company's focus on speed, quality, and operational predictability, combined with its U.S.-based manufacturing footprint, positions it to meet increasing industry demand for reliable and responsive CDMO partners.</p>
<div class="lb-trans"><p>McCullough Wood 的任命正值藥明康德繼續擴大其運營，以支持生物製藥公司在整個開發生命週期中的需求，從早期項目到商業製造。該公司專注於速度、質量和運營可預測性，加上其美國本土的製造能力，使其能夠滿足行業對可靠和響應迅速的 CDMO 合作伙伴日益增長的需求。</p>
</div><p>&#34;I'm excited to join Avid at such a pivotal point in its growth,&#34; said McCullough Wood. &#34;The company has built a strong reputation for quality, flexibility, and partnership. I look forward to working with the team to expand our commercial reach, deepen client relationships, and help bring more therapies to patients.&#34;</p>
<div class="lb-trans"><p>&#34;我很高興在藥明康德如此關鍵的增長時刻加入，&#34;McCullough Wood 表示。&#34;公司在質量、靈活性和合作方面建立了良好的聲譽。我期待與團隊合作，擴大我們的商業覆蓋面，加深客户關係，並幫助將更多療法帶給患者。&#34;</p>
</div><p>With McCullough Wood's leadership, Avid will continue advancing its mission to set the standard for quality and partnership in biologics manufacturing, enabling the delivery of therapies that transform patient lives.</p>
<div class="lb-trans"><p>在 McCullough Wood 的領導下，藥明康德將繼續推進其使命，設定生物製劑製造的質量和合作標準，使能夠提供改變患者生活的療法。</p>
</div><p><strong>About Avid</strong></p>
<div class="lb-trans"><p><strong>關於藥明康德</strong></p>
</div><p>Avid Bioservices is a global contract development and manufacturing organization (CDMO) specializing in mammalian cell-culture manufacturing. Headquartered in the U.S. with a flawless FDA record, Avid is trusted by biopharmaceutical innovators worldwide for its agility, quality, and ability to navigate complex global regulatory landscapes. With experience supporting both emerging biotech and large multinational pharma companies, Avid provides end-to-end solutions from development through commercial supply.</p>
<div class="lb-trans"><p>藥明康德是一家全球合同開發和製造組織（CDMO），專注於哺乳動物細胞培養製造。總部位於美國，擁有無可挑剔的 FDA 記錄，藥明康德因其敏捷性、質量和應對複雜全球監管環境的能力而受到全球生物製藥創新者的信任。藥明康德擁有支持新興生物科技和大型跨國製藥公司的經驗，提供從開發到商業供應的端到端解決方案。</p>
</div><p>Avid By the Numbers:</p>
<div class="lb-trans"><p>藥明康德的數字：</p>
</div><p>More than 600 batches manufactured</p>
<div class="lb-trans"><p>製造超過 600 批次</p>
</div><p>Over 275 commercial batches delivered globally</p>
<div class="lb-trans"><p>全球交付超過 275 批次商業產品</p>
</div><p>7+ approved commercial products</p>
<div class="lb-trans"><p>7 個以上獲批的商業產品</p>
</div><p>10 successful pre-approval/pre-license inspections across major regulatory agencies</p>
<div class="lb-trans"><p>在主要監管機構進行 10 次成功的預批准/預許可檢查</p>
</div><p>SOURCE Avid Bioservices</p>
<div class="lb-trans"><p>來源：藥明康德</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTExJk5ld3NJdGVtSWQ9TEE1NjM3MSZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTExMzI3UFJfTkVXU19VU1BSX19fX19MQTU2Mzcx" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=LA56371&amp;Transmission_Id=202605111327PR_NEWS_USPR_____LA56371&amp;DateId=20260511"/></p>

Avid Bioservices 任命 Kerri McCullough Wood 為首席商務官